腫瘍学におけるコンパニオン診断検査の世界市場

腫瘍学におけるコンパニオン診断検査の世界市場は2030年までに100億米ドルに達する見込み

2024年に63億米ドルと推定される腫瘍学におけるコンパニオン診断検査の世界市場は、2024年から2030年にかけてCAGR 8.1%で成長し、2030年には100億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるタンパク質検出-免疫組織化学は、CAGR6.9％を記録し、分析期間終了までに41億米ドルに達すると予測されます。DNA検出-ポリメラーゼ連鎖反応（Polymerase Chain Reaction）分野の成長率は、分析期間でCAGR 9.7％と推定されます。

米国市場は17億米ドルと推定、中国はCAGR12.4％で成長予測

米国の腫瘍学におけるコンパニオン診断検査市場は2024年に17億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに21億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは12.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ4.2%と7.7%と予測されています。欧州では、ドイツがCAGR 5.4%で成長すると予測されています。

世界の腫瘍学におけるコンパニオン診断検査市場- 主要動向と促進要因まとめ

コンパニオン診断検査が世界のがん治療に革命をもたらす理由とは？

腫瘍学におけるコンパニオン診断検査は、特定の治療法を個々の患者プロファイルに合わせることで、がんの発見、分類、治療方法を根本的に変えています。これらの検査は、標的治療に対する患者の反応を予測するバイオマーカーを同定し、治療をより正確に、効果的に、個別化します。従来の診断アプローチとは異なり、コンパニオン診断薬は、臨床医が患者とその患者に最も有効な治療法をマッチングさせることを可能にし、同時に効果のない治療や有害な可能性のある治療を回避することを可能にします。これは、腫瘍学において、画一的なモデルから精密医療へのアプローチへの大きな転換を意味します。がん種が遺伝子変異や分子シグネチャーによってますます細分化されるにつれて、これらの診断法は治療決定の指針として不可欠なものとなりつつあります。例えば、乳がんのHER2発現や非小細胞肺がんのEGFR変異を検出する検査は、特定の生物学的製剤やチロシンキナーゼ阻害剤の適格性を判断するのに役立ちます。このような検査の臨床的価値は、予後が分子プロファイルと密接に結びついているような、遺伝的要因が明確に定義されたがんにおいて特に高いです。製薬企業がよりターゲットを絞ったがん治療薬を開発するにつれ、コンパニオン診断薬の共同開発は、規制当局の承認を得て臨床試験の成功率を向上させるための標準的な戦略として台頭してきています。これらの検査が早期がんの管理に組み込まれることで、タイムリーな介入、予後の改善、患者のQOLの向上も促進されます。このような臨床的、経済的、技術的メリットの合流により、コンパニオン診断検査は、現代のがん医療において不可欠なツールとなっています。

技術革新はコンパニオン診断薬の進歩をどのように促進しているか？

技術革新はコンパニオン診断の精度、スピード、有用性を高める上で極めて重要な役割を果たしています。ゲノムシークエンシング、特に次世代シークエンシング（NGS）の進歩は、1つのサンプルから複数のがん関連変異を同定する方法に革命をもたらしました。この能力により、様々な実用的バイオマーカーを同時にスクリーニングするマルチプレックスアッセイの開発が可能となり、腫瘍の分子ランドスケープのより包括的な理解が得られるようになりました。さらに、リキッドバイオプシー技術の出現により、血液やその他の体液を用いた非侵襲的な検査が可能になり、多くの症例で組織生検が不要になり、治療反応や病勢進行のモニタリングが容易になりました。機械学習と人工知能がコンパニオン診断プラットフォームに組み込まれ、複雑なゲノムデータを解析し、パターンを検出し、臨床上の意思決定をサポートする実用的な洞察を生み出しています。デジタル病理学および画像診断技術もまた、視覚的データと分子プロファイルを統合することにより、バイオマーカー同定の向上に寄与しています。さらに、検査室のワークフローにおける自動化は、スループットを向上させ、エラー率を減少させ、納期を短縮し、これらの検査を臨床医や患者にとってより利用しやすいものにしています。コンパニオン診断薬は現在、デジタルヘルスプラットフォームや電子カルテに統合され、診断ラボ、腫瘍医、治療センター間のシームレスな連携を促進しています。このような技術的進歩は、検査の感度と特異度を向上させるだけでなく、がんの種類を問わず検出可能なバイオマーカーの範囲を拡大しています。技術革新が加速するにつれて、コンパニオン診断検査はよりスケーラブルで費用対効果の高いものとなり、世界規模での日常的ながん診療への統合を支えています。

がん領域におけるコンパニオン診断薬の成長を形成している市場動向および規制動向は？

がん領域におけるコンパニオン診断薬市場の成長は、規制政策、支払者の償還、共同商業化戦略におけるダイナミックなシフトによって形成されています。FDA、EMA、PMDAのような規制機関は、治療の意思決定におけるコンパニオン診断薬の重要な役割をますます認識するようになっており、医薬品とそれに対応する診断薬の共同承認の枠組みを確立しています。このような並行承認経路は、製薬企業と診断薬企業が早期段階からパートナーシップを結び、バイオマーカー開発を創薬プロセスに組み込むことを後押ししています。特に医療制度が、治療失敗率や副作用を低減する精密医療アプローチに関連する長期的なコスト削減を認識し始めたことから、償還政策はより広範な検査利用を支援するように進化しています。価値ベースのヘルスケアモデルは臨床的有用性を強調し、診断薬が治療を導き転帰を改善する上で明確な有用性を示すことを要求しています。これに対応するため、診断薬開発企業は実際のエビデンス研究や医療経済学的分析に投資し、支払者や医療提供者への価値提案を強化しています。利害関係者が技術革新と手頃な価格やデータの相互運用性とのバランスを模索する中、知的財産やデータ共有契約も業界連携の中心的存在となりつつあります。市場競争は激化しており、大手体外診断薬企業も中小の分子診断薬新興企業も、増え続ける標的治療薬のバイオマーカーパネルの開発を競っています。これと並行して、政府やヘルスケア機関は、ゲノム検査へのアクセスを拡大し、バイオマーカー研究を支援する国家データベースを構築するため、プレシジョン・オンコロジー・イニシアチブを立ち上げています。このような規制および市場の動きは、特に発生頻度の高いがんや先進的な治療領域において、コンパニオン診断薬の拡大にとってより有利な環境を作り出しています。

腫瘍学におけるコンパニオン診断検査の需要を世界的に牽引している要因とは？

腫瘍学におけるコンパニオン診断検査市場の成長は、進化するがん治療の情勢を反映する臨床的、技術的、人口統計的、商業的要因の収束によってもたらされます。世界のがん罹患率の増加、特に固形がんや血液悪性腫瘍の罹患率の増加は、治療を個別化し治療結果を改善する診断薬に対する強い需要を生み出しています。がん治療が標的療法や免疫療法にシフトする中、コンパニオン診断薬は、適切な治療を受ける適切な患者を特定し、それによって有効性を高め、毒性を最小限に抑えるために不可欠なものとなりつつあります。精密医療に対する腫瘍医や患者の意識の開拓は、特に医療インフラの整った先進国市場において、検査の採用を加速させています。ターゲットを絞ったがん治療薬のパイプラインは拡大しており、その多くは承認取得のためにバイオマーカーの検証を必要とするため、コンパニオン診断薬の共同開発に拍車がかかっています。製薬会社は臨床試験への登録を改善し、薬剤の上市と診断の準備を合わせるために診断薬企業との提携に投資しています。NGS、AIベースの分析、デジタルヘルス統合などの技術的進歩により、診断の迅速化、高精度化、導入の容易化が進んでいます。精密医療への取り組みに対する政府の支援と良好な償還動向は、市場の成長にさらに寄与しています。さらに、分子検査施設の普及と診断サービスの分散化により、新興市場でもコンパニオン診断がより利用しやすくなっています。世界中のヘルスケアシステムが、より個別化された、データ主導のがん治療へのアプローチを目指す中、コンパニオン診断薬は、分子レベルでの知見と治療方針の決定とのギャップを埋める不可欠なツールとして台頭してきています。これらの要因が相まって、コンパニオン診断薬市場の急速な拡大が強調され、腫瘍学の将来における中心的な役割を担っています。

セグメント

検出技術（タンパク質検出-免疫組織化学、DNA検出-ポリメラーゼ連鎖反応、次世代シーケンシング、インサイチュハイブリダイゼーション、その他の検出技術）、バイオマーカー（EGFRバイオマーカー、KRASバイオマーカー、HER2バイオマーカー、BRAF V600Eバイオマーカー、その他のバイオマーカー）、がん種（乳がん、肺がん、大腸がん、肝がん、メラノーマ、その他のがん種）;エンドユーザー（病院エンドユーザー、専門クリニックエンドユーザー、診断ラボエンドユーザー、その他のエンドユーザー）

調査対象企業の例

• Abbott Laboratories
• Agilent Technologies
• Almac Group
• ARUP Laboratories
• bioMerieux
• Bio-Rad aboratories
• Caris Life Sciences
• Danaher Corporation
• Exact Sciences Corporation
• Foundation Medicine
• Guardant Health
• Illumina
• Invitae Corporation
• Myriad Genetics
• NeoGenomics Laboratories
• Qiagen
• Roche Diagnostics
• Sysmex Corporation
• Thermo Fisher Scientific
• Veracyte

AI統合

Global Industry Analystsは、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Companion Diagnostic Tests in Oncology Market to Reach US$10.0 Billion by 2030

The global market for Companion Diagnostic Tests in Oncology estimated at US$6.3 Billion in the year 2024, is expected to reach US$10.0 Billion by 2030, growing at a CAGR of 8.1% over the analysis period 2024-2030. Protein Detection-Immunohistochemistry, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$4.1 Billion by the end of the analysis period. Growth in the DNA Detection-Polymerase Chain Reaction segment is estimated at 9.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.7 Billion While China is Forecast to Grow at 12.4% CAGR

The Companion Diagnostic Tests in Oncology market in the U.S. is estimated at US$1.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2030 trailing a CAGR of 12.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.2% and 7.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.4% CAGR.

Global Companion Diagnostic Tests in Oncology Market - Key Trends & Drivers Summarized

Why Are Companion Diagnostic Tests Revolutionizing Cancer Treatment Worldwide?

Companion diagnostic tests in oncology are fundamentally transforming how cancers are detected, classified, and treated by aligning specific therapies with individual patient profiles. These tests identify biomarkers that predict a patient’s response to a targeted therapy, making treatment more precise, effective, and personalized. Unlike conventional diagnostic approaches, companion diagnostics allow clinicians to match patients with the therapies most likely to benefit them while avoiding ineffective or potentially harmful treatments. This represents a major shift in oncology from a one-size-fits-all model to a precision medicine approach. As cancer types become increasingly segmented by genetic mutations and molecular signatures, these diagnostics are becoming indispensable in guiding therapeutic decisions. For instance, tests that detect HER2 expression in breast cancer or EGFR mutations in non-small cell lung cancer help determine eligibility for specific biologics or tyrosine kinase inhibitors. The clinical value of such testing is particularly high in cancers with well-defined genetic drivers, where outcomes are closely tied to molecular profiles. As pharmaceutical companies develop more targeted oncology drugs, the co-development of companion diagnostics is emerging as a standard strategy to gain regulatory approval and improve clinical trial success rates. The integration of these tests into early-stage cancer management is also facilitating timely intervention, improving prognosis, and enhancing patient quality of life. This confluence of clinical, economic, and technological benefits is positioning companion diagnostic tests as essential tools in the modern oncology care continuum.

How Are Technological Innovations Driving Advancements in Companion Diagnostics?

Technological innovation is playing a pivotal role in enhancing the accuracy, speed, and utility of companion diagnostic tests in oncology. Advances in genomic sequencing, especially next-generation sequencing (NGS), have revolutionized how multiple cancer-related mutations can be identified from a single sample. This capability has made it feasible to develop multiplexed assays that screen for various actionable biomarkers simultaneously, providing a more comprehensive understanding of the tumor’s molecular landscape. Additionally, the emergence of liquid biopsy technology is enabling non-invasive testing through blood or other bodily fluids, eliminating the need for tissue biopsies in many cases and allowing for easier monitoring of treatment response and disease progression. Machine learning and artificial intelligence are being incorporated into companion diagnostic platforms to analyze complex genomic data, detect patterns, and generate actionable insights that support clinical decision-making. Digital pathology and imaging techniques are also contributing to improved biomarker identification by integrating visual data with molecular profiles. Furthermore, automation in laboratory workflows is increasing throughput, reducing error rates, and shortening turnaround times, making these tests more accessible to clinicians and patients. Companion diagnostics are now being integrated into digital health platforms and electronic medical records, facilitating seamless coordination between diagnostic labs, oncologists, and treatment centers. These technological advances are not only improving test sensitivity and specificity but are also expanding the range of detectable biomarkers across cancer types. As innovation accelerates, companion diagnostic tests are becoming more scalable and cost-effective, supporting their integration into routine oncology practice on a global scale.

What Market and Regulatory Trends Are Shaping the Growth of Companion Diagnostics in Oncology?

The growth of the companion diagnostic market in oncology is being shaped by dynamic shifts in regulatory policy, payer reimbursement, and collaborative commercialization strategies. Regulatory agencies such as the FDA, EMA, and PMDA are increasingly recognizing the critical role of companion diagnostics in therapeutic decision-making and have established frameworks for co-approval of drugs and their corresponding diagnostic tests. These parallel approval pathways are encouraging pharmaceutical and diagnostics companies to engage in early-stage partnerships, integrating biomarker development into the drug discovery process. Reimbursement policies are evolving to support broader test accessibility, especially as health systems begin to recognize the long-term cost savings associated with precision medicine approaches that reduce treatment failure rates and adverse effects. Value-based healthcare models are emphasizing clinical utility, requiring that diagnostics demonstrate clear benefit in guiding treatment and improving outcomes. In response, diagnostic developers are investing in real-world evidence studies and health economics analyses to strengthen their value proposition to payers and providers. Intellectual property and data-sharing agreements are also becoming central to industry collaborations, as stakeholders seek to balance innovation with affordability and data interoperability. Market competition is intensifying, with both large in vitro diagnostic firms and smaller molecular diagnostics startups racing to develop biomarker panels for a growing list of targeted therapies. In parallel, governments and healthcare institutions are launching precision oncology initiatives to expand access to genomic testing and build national databases that support biomarker research. These regulatory and market forces are collectively creating a more favorable environment for the expansion of companion diagnostics, especially in high-incidence cancers and advanced therapeutic areas.

What Factors Are Driving the Global Demand for Companion Diagnostic Tests in Oncology?

The growth in the companion diagnostic tests in oncology market is driven by a convergence of clinical, technological, demographic, and commercial factors that reflect the evolving landscape of cancer treatment. The increasing global cancer burden, particularly the rising incidence of solid tumors and hematologic malignancies, is creating a strong demand for diagnostics that can personalize therapy and improve treatment outcomes. As cancer care shifts toward targeted and immunotherapies, companion diagnostics are becoming essential for identifying the right patients for the right treatments, thereby enhancing efficacy and minimizing toxicity. Growing awareness among oncologists and patients about precision medicine is accelerating test adoption, particularly in developed markets with advanced healthcare infrastructure. The expanding pipeline of targeted oncology drugs, many of which require biomarker validation for regulatory approval, is fueling the co-development of companion diagnostics. Pharmaceutical companies are investing in partnerships with diagnostics firms to improve clinical trial enrollment and align drug launches with diagnostic readiness. Technological advancements such as NGS, AI-based analytics, and digital health integration are making diagnostics faster, more accurate, and easier to deploy. Government support for precision medicine initiatives and favorable reimbursement trends are further contributing to market growth. Additionally, the proliferation of molecular testing laboratories and the decentralization of diagnostic services are making companion diagnostics more accessible in emerging markets. As healthcare systems worldwide strive for more personalized, data-driven approaches to cancer care, companion diagnostic tests are emerging as indispensable tools that bridge the gap between molecular insights and therapeutic decisions. These factors collectively underscore the rapid expansion of this market and its central role in the future of oncology.

SCOPE OF STUDY:

The report analyzes the Companion Diagnostic Tests in Oncology market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Detection Technique (Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization, Other Detection Techniques); Biomarker (EGFR Biomarker, KRAS Biomarker, HER2 Biomarker, BRAF V600E Biomarker, Other Biomarkers); Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma, Other Cancer Types); End-User (Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

• Abbott Laboratories
• Agilent Technologies
• Almac Group
• ARUP Laboratories
• bioMerieux
• Bio-Rad aboratories
• Caris Life Sciences
• Danaher Corporation
• Exact Sciences Corporation
• Foundation Medicine
• Guardant Health
• Illumina
• Invitae Corporation
• Myriad Genetics
• NeoGenomics Laboratories
• Qiagen
• Roche Diagnostics
• Sysmex Corporation
• Thermo Fisher Scientific
• Veracyte

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Companion Diagnostic Tests in Oncology - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Demand for Targeted Cancer Therapies Propels Growth in Companion Diagnostic Development
  • Precision Medicine Initiatives Expand Addressable Market for Tumor-Specific Diagnostic Platforms
  • Biomarker Discovery Advancements Throw the Spotlight on Next-Generation Sequencing-Based CDx Solutions
  • Immuno-Oncology Pipeline Growth Accelerates Demand for Predictive Companion Diagnostics
  • Liquid Biopsy and Minimally Invasive Testing Trends Spur Innovation in Blood-Based Companion Diagnostics
  • Rising Incidence of Solid Tumors and Rare Cancers Generates Demand for Indication-Specific CDx Tests
  • Clinical Trial Complexity Drives Uptake of Companion Diagnostics in Patient Stratification Strategies
  • Global Harmonization of Regulatory Pathways Supports Cross-Border Launch of CDx-Linked Therapies
  • Data-Driven Oncology Platforms Propel Growth in AI-Supported and Integrated CDx Solutions
  • Pharma Investment in Personalized Oncology Strategies Sustains Long-Term Demand for CDx Collaborations
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Companion Diagnostic Tests in Oncology Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Companion Diagnostic Tests in Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Companion Diagnostic Tests in Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Protein Detection-Immunohistochemistry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Protein Detection-Immunohistochemistry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Protein Detection-Immunohistochemistry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for DNA Detection-Polymerase Chain Reaction by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for DNA Detection-Polymerase Chain Reaction by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for DNA Detection-Polymerase Chain Reaction by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Next-Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Next-Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Next-Generation Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for In-Situ Hybridization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for In-Situ Hybridization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for In-Situ Hybridization by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Detection Techniques by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Detection Techniques by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Other Detection Techniques by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Other Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for EGFR Biomarker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for EGFR Biomarker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for EGFR Biomarker by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for KRAS Biomarker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for KRAS Biomarker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for KRAS Biomarker by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for HER2 Biomarker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for HER2 Biomarker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for HER2 Biomarker by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for BRAF V600E Biomarker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for BRAF V600E Biomarker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for BRAF V600E Biomarker by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 37: World 16-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 40: World 16-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 43: World 16-Year Perspective for Colorectal Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Liver Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Liver Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 46: World 16-Year Perspective for Liver Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 49: World 16-Year Perspective for Melanoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 50: World Recent Past, Current & Future Analysis for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 51: World Historic Review for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 52: World 16-Year Perspective for Other Cancer Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 53: World Recent Past, Current & Future Analysis for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 54: World Historic Review for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 55: World 16-Year Perspective for Hospitals End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 56: World Recent Past, Current & Future Analysis for Specialty Clinics End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 57: World Historic Review for Specialty Clinics End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 58: World 16-Year Perspective for Specialty Clinics End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 59: World Recent Past, Current & Future Analysis for Diagnostic Labs End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 60: World Historic Review for Diagnostic Labs End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 61: World 16-Year Perspective for Diagnostic Labs End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 62: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 63: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 64: World 16-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Companion Diagnostic Tests in Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 65: USA Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: USA Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 67: USA 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
  • TABLE 68: USA Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: USA Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 70: USA 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
  • TABLE 71: USA Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: USA Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 73: USA 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
  • TABLE 74: USA Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: USA Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 76: USA 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 77: Canada Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Canada Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 79: Canada 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
  • TABLE 80: Canada Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Canada Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 82: Canada 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
  • TABLE 83: Canada Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Canada Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 85: Canada 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
  • TABLE 86: Canada Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Canada Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 88: Canada 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
• JAPAN
  • Companion Diagnostic Tests in Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 89: Japan Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Japan Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 91: Japan 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
  • TABLE 92: Japan Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Japan Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 94: Japan 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
  • TABLE 95: Japan Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Japan Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 97: Japan 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
  • TABLE 98: Japan Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Japan Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 100: Japan 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
• CHINA
  • Companion Diagnostic Tests in Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 101: China Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: China Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 103: China 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
  • TABLE 104: China Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: China Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 106: China 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
  • TABLE 107: China Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: China Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 109: China 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
  • TABLE 110: China Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: China Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 112: China 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
• EUROPE
  • Companion Diagnostic Tests in Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 113: Europe Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 114: Europe Historic Review for Companion Diagnostic Tests in Oncology by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 115: Europe 16-Year Perspective for Companion Diagnostic Tests in Oncology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 116: Europe Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Europe Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 118: Europe 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
  • TABLE 119: Europe Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Europe Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 121: Europe 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
  • TABLE 122: Europe Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Europe Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 124: Europe 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
  • TABLE 125: Europe Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Europe Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 127: Europe 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
• FRANCE
  • Companion Diagnostic Tests in Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 128: France Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: France Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 130: France 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
  • TABLE 131: France Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: France Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 133: France 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
  • TABLE 134: France Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: France Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 136: France 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
  • TABLE 137: France Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: France Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 139: France 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
• GERMANY
  • Companion Diagnostic Tests in Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 140: Germany Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Germany Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 142: Germany 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
  • TABLE 143: Germany Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Germany Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 145: Germany 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
  • TABLE 146: Germany Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Germany Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 148: Germany 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
  • TABLE 149: Germany Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Germany Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 151: Germany 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 152: Italy Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Italy Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 154: Italy 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
  • TABLE 155: Italy Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Italy Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 157: Italy 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
  • TABLE 158: Italy Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Italy Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 160: Italy 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
  • TABLE 161: Italy Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Italy Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 163: Italy 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Companion Diagnostic Tests in Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 164: UK Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: UK Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 166: UK 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
  • TABLE 167: UK Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: UK Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 169: UK 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
  • TABLE 170: UK Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: UK Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 172: UK 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
  • TABLE 173: UK Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: UK Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 175: UK 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 176: Spain Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Spain Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 178: Spain 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
  • TABLE 179: Spain Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Spain Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 181: Spain 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
  • TABLE 182: Spain Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Spain Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 184: Spain 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
  • TABLE 185: Spain Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Spain Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 187: Spain 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 188: Russia Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Russia Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 190: Russia 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
  • TABLE 191: Russia Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Russia Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 193: Russia 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
  • TABLE 194: Russia Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Russia Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 196: Russia 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
  • TABLE 197: Russia Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Russia Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 199: Russia 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 200: Rest of Europe Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Rest of Europe Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 202: Rest of Europe 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
  • TABLE 203: Rest of Europe Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Rest of Europe Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 205: Rest of Europe 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
  • TABLE 206: Rest of Europe Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Rest of Europe Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 208: Rest of Europe 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
  • TABLE 209: Rest of Europe Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Rest of Europe Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 211: Rest of Europe 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Companion Diagnostic Tests in Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 212: Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 213: Asia-Pacific Historic Review for Companion Diagnostic Tests in Oncology by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 214: Asia-Pacific 16-Year Perspective for Companion Diagnostic Tests in Oncology by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 215: Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Asia-Pacific Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 217: Asia-Pacific 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
  • TABLE 218: Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Asia-Pacific Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 220: Asia-Pacific 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
  • TABLE 221: Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Asia-Pacific Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 223: Asia-Pacific 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
  • TABLE 224: Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Asia-Pacific Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 226: Asia-Pacific 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Companion Diagnostic Tests in Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 227: Australia Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Australia Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 229: Australia 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
  • TABLE 230: Australia Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Australia Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 232: Australia 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
  • TABLE 233: Australia Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Australia Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 235: Australia 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
  • TABLE 236: Australia Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Australia Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 238: Australia 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
• INDIA
  • Companion Diagnostic Tests in Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 239: India Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: India Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 241: India 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
  • TABLE 242: India Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: India Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 244: India 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
  • TABLE 245: India Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: India Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 247: India 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
  • TABLE 248: India Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: India Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 250: India 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 251: South Korea Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: South Korea Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 253: South Korea 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
  • TABLE 254: South Korea Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: South Korea Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 256: South Korea 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
  • TABLE 257: South Korea Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: South Korea Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 259: South Korea 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
  • TABLE 260: South Korea Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: South Korea Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 262: South Korea 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 263: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Rest of Asia-Pacific Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 265: Rest of Asia-Pacific 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
  • TABLE 266: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Rest of Asia-Pacific Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 268: Rest of Asia-Pacific 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
  • TABLE 269: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Rest of Asia-Pacific Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 271: Rest of Asia-Pacific 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
  • TABLE 272: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Rest of Asia-Pacific Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 274: Rest of Asia-Pacific 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Companion Diagnostic Tests in Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 275: Latin America Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 276: Latin America Historic Review for Companion Diagnostic Tests in Oncology by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 277: Latin America 16-Year Perspective for Companion Diagnostic Tests in Oncology by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 278: Latin America Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Latin America Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 280: Latin America 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
  • TABLE 281: Latin America Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Latin America Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 283: Latin America 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
  • TABLE 284: Latin America Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Latin America Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 286: Latin America 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
  • TABLE 287: Latin America Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Latin America Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 289: Latin America 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 290: Argentina Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Argentina Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 292: Argentina 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
  • TABLE 293: Argentina Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Argentina Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 295: Argentina 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
  • TABLE 296: Argentina Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Argentina Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 298: Argentina 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
  • TABLE 299: Argentina Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Argentina Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 301: Argentina 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 302: Brazil Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Brazil Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 304: Brazil 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
  • TABLE 305: Brazil Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Brazil Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 307: Brazil 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
  • TABLE 308: Brazil Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Brazil Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 310: Brazil 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
  • TABLE 311: Brazil Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Brazil Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 313: Brazil 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 314: Mexico Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Mexico Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 316: Mexico 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
  • TABLE 317: Mexico Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Mexico Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 319: Mexico 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
  • TABLE 320: Mexico Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Mexico Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 322: Mexico 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
  • TABLE 323: Mexico Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Mexico Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 325: Mexico 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 326: Rest of Latin America Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Rest of Latin America Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 328: Rest of Latin America 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
  • TABLE 329: Rest of Latin America Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Rest of Latin America Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 331: Rest of Latin America 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
  • TABLE 332: Rest of Latin America Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Rest of Latin America Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 334: Rest of Latin America 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
  • TABLE 335: Rest of Latin America Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Rest of Latin America Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 337: Rest of Latin America 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Companion Diagnostic Tests in Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 338: Middle East Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 339: Middle East Historic Review for Companion Diagnostic Tests in Oncology by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 340: Middle East 16-Year Perspective for Companion Diagnostic Tests in Oncology by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 341: Middle East Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Middle East Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 343: Middle East 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
  • TABLE 344: Middle East Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Middle East Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 346: Middle East 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
  • TABLE 347: Middle East Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Middle East Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 349: Middle East 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
  • TABLE 350: Middle East Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Middle East Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 352: Middle East 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 353: Iran Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Iran Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 355: Iran 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
  • TABLE 356: Iran Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Iran Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 358: Iran 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
  • TABLE 359: Iran Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Iran Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 361: Iran 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
  • TABLE 362: Iran Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Iran Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 364: Iran 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 365: Israel Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Israel Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 367: Israel 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
  • TABLE 368: Israel Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 369: Israel Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 370: Israel 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
  • TABLE 371: Israel Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 372: Israel Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 373: Israel 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
  • TABLE 374: Israel Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 375: Israel Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 376: Israel 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 377: Saudi Arabia Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 378: Saudi Arabia Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 379: Saudi Arabia 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
  • TABLE 380: Saudi Arabia Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 381: Saudi Arabia Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 382: Saudi Arabia 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
  • TABLE 383: Saudi Arabia Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 384: Saudi Arabia Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 385: Saudi Arabia 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
  • TABLE 386: Saudi Arabia Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Saudi Arabia Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 388: Saudi Arabia 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 389: UAE Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 390: UAE Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 391: UAE 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
  • TABLE 392: UAE Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 393: UAE Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 394: UAE 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
  • TABLE 395: UAE Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 396: UAE Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 397: UAE 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
  • TABLE 398: UAE Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 399: UAE Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 400: UAE 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 401: Rest of Middle East Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Rest of Middle East Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 403: Rest of Middle East 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
  • TABLE 404: Rest of Middle East Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 405: Rest of Middle East Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 406: Rest of Middle East 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
  • TABLE 407: Rest of Middle East Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 408: Rest of Middle East Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 409: Rest of Middle East 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
  • TABLE 410: Rest of Middle East Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 411: Rest of Middle East Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 412: Rest of Middle East 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
• AFRICA
  • Companion Diagnostic Tests in Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 413: Africa Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 414: Africa Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 415: Africa 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
  • TABLE 416: Africa Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 417: Africa Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 418: Africa 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
  • TABLE 419: Africa Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 420: Africa Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 421: Africa 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
  • TABLE 422: Africa Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 423: Africa Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 424: Africa 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030

IV. COMPETITION